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Abstract
In a cohort study among 2751 members (71.5% females) of the German and Swiss RLS patient organizations changes in
restless legs syndrome (RLS) severity over time was assessed and the impact on quality of life, sleep quality and depressive
symptoms was analysed. A standard set of scales (RLS severity scale IRLS, SF-36, Pittsburgh Sleep Quality Index and the
Centre for Epidemiologic Studies Depression Scale) in mailed questionnaires was repeatedly used to assess RLS severity and
health status over time and a 7-day diary once to assess short-term variations. A clinically relevant change of the RLS severity
was defined by a change of at least 5 points on the IRLS scale. During 36 months follow-up minimal improvement of RLS
severity between assessments was observed. Men consistently reported higher severity scores. RLS severity increased with
age reaching a plateau in the age group 45–54 years. During 3 years 60.2% of the participants had no relevant (65 points)
change in RLS severity. RLS worsening was significantly related to an increase in depressive symptoms and a decrease in
sleep quality and quality of life. The short-term variation showed distinctive circadian patterns with rhythm magnitudes
strongly related to RLS severity. The majority of participants had a stable course of severe RLS over three years. An increase
in RLS severity was accompanied by a small to moderate negative, a decrease by a small positive influence on quality of life,
depressive symptoms and sleep quality.
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Introduction
Restless legs syndrome is a common sleep disorder with
prevalences between 5 and 10% in population based studies in
Europe and North America [1–4].
The prevalence of RLS increases with age, while the course of
the disease, i.e. the pattern of symptom severity over time, is
unclear. Assessing the latter has been predominantly done in
clinical trials testing specific single medication over follow-up
periods between one week and 35 months [5]. Thus, it is unknown
if RLS is a chronic condition progressing slowly after onset over
the life span or expresses other patterns over long time periods in
individual patients depending on life events or associated diseases.
Knowledge about the disease course is important because many
studies have shown that RLS influences different aspects of daily
living when assessed in cross-sectional studies [6]. Beside
reductions in sleep quality, activities of daily living and quality of
life it includes a 2- to 4-fold risk for depressive disorders in RLS
patients compared to healthy individuals [7,8]. However, studies
assessing symptom severity in affected individuals repeatedly over
longer time periods are lacking. Thus, the basis for patient
information on the long-term prognosis is limited to the experience
of the respective physician with long term treatment. Better
knowledge of short-term fluctuations and long-term severity
patterns however might enable an individual to better cope with
the consequences of the disease.
Aim of this analysis was to evaluate individual variations of RLS
severity over a short, i.e. 7-day, and a long, i.e. 36-month time-
period and to analyse the impact of these variations on self
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perceived quality of life, sleep quality and depressive symptoms in
a cohort of German and Swiss RLS patients.
Methods
Subjects
The Course of RLS-Study (COR-S) was started in fall 2007 and
is conducted by mailed questionnaires. All 4385 members of the
RLS support-group in Germany (RLS e.V. Deutsche Restless Legs
Vereinigung) and the 633 members of the Swiss RLS Patient
Association (Schweizerische Restless Legs Selbsthilfegruppe), were
once contacted by mail, and invited to participate in the study.
2562 members of the German Restless Legs group (response
proportion 58.4%), and 254 members of the Swiss support group
(response proportion 40.1%) accepted the invitation, yielding a
COR-S population of 2816 participants (overall response 56.1%).
Written informed consent was obtained from all participants. A
small proportion (6.7%) of the German participants had under-
gone a standardized, detailed diagnostic work up in one of 5
specialized German RLS centers. Participants from these ARE-
LESS centers underwent a physical examination including a
complete neurological status assessment by an RLS expert.
Laboratory markers including ferritine were analysed. Optionally,
a polysomnography was done. Inclusion of these participants
enabled the definition of a RLS group that had received a
common diagnostic ‘gold standard’ procedure in the establishment
of the RLS diagnosis. This analysis includes data from the baseline
questionnaire (Q1) and the six- (Q2), 12- (Q3), 24- (Q4) and 36-
months follow-up questionnaires. During this time period a total of
78 participants had died.
Instruments
Ethics statement. The study protocol was approved by the
local ethics committee of the Medical Faculty at the University of
Muenster.
In all five questionnaires a common set of instruments and scales
was used to assess RLS severity and different aspects of self-
perceived health status. All scales applied in the respective
German version had been validated in prior studies and are
frequently used in RLS studies.
To assess the severity of RLS the International RLS Study
Group (IRLSSG) rating scale for severity of RLS (IRLS) was used
[9]. An IRLS score between 1 and 10 points is considered as mild,
between 11 and 20 moderate, between 21 and 30 severe and
between 31 and 40 points as very severe RLS.
In the 6-month questionnaire (Q2) a 7-day diary was included
to assess short-term variations in the two key RLS symptoms
‘‘dysaesthesia’’ and ‘‘urge to move’’. Splitting every day into four
time periods the RLS symptoms were rated by the participants in
each time period as either being mild or moderate or severe.
To assess the self perceived health status the German version of
the Short Form-36 Health Survey (SF-36) was used [10].
Sleep related problems were assessed with the Pittsburgh Sleep
Quality Index (PSQI) [11]. Varying between 0 and 21 points a
PSQI summary score $5 is considered to indicate sleep
disturbances.
Depressive symptoms were rated using the Center for Epide-
miological Studies Depression Scale (CES-D) [12]. A cut-off of
$16 points is frequently used to identify clinical relevant
depression, i.e. an acute episode of major depression.
In all COR-S questionnaires information on sociodemographic
factors, health related risk factors, comorbidities and health
services utilization was collected.
Statistical analysis
To analyse changes in health status scores data of four time
points, baseline questionnaire (Q1), 12- (Q3), 24- (Q4) and 36-
months were applied to assess one-way repeated measures
ANOVA. In addition we used the difference in the RLS severity
score between baseline and 36-months to define long-term change.
Following arguments by Trenkwalder [13] we defined as a
‘‘clinically relevant change’’ a decrease or increase of more than 5
points on the IRLS. This cut-off is a conservative definition, since
some RLS drugs have been licensed with a minimum change of 3
points difference in the IRLS compared to placebo after 12 weeks
of therapy [13]. Subsequently one way analysis of variance
(ANOVA) was applied to test for differences in the means of the
respective health status scores at each time point, according to
three levels of change (improvement, unchanged, worsening).
Multivariable linear regression was performed to analyse the
impact of change in RLS severity on changes in sleep quality,
quality of life and depression scores. These models were adjusted
for age at baseline, gender, duration of RLS disease and number of
RLS medications at baseline. A p-value ,0.05 was considered
Table 1. Characteristics of the COR-Study participants at
baseline.
Baseline questionnaire(Q1) all women men
Sex, n (%) 2751 (100) 1967 (71.5) 783 (28.5)
Mean age (range), years 65.9(27–96) 65.5(29–96) 66.9(27–94)
RLS history
Duration of RLS symptoms, years mean 22.1 22.7 20.7
Time since diagnosis, years mean 8.3 8.3 8.5
RLS diagnosed by a neurologist,% 60.1 59.7 61.1
RLS treated by a neurologist,% 71.0 71.4 70.0
Medication
RLS medication use,% 93.8 93.9 93.7
Other medication use,% 85.6 87.7 80.1
No medication at all,% 1.4 1.3 1.8
Smoking habits
Current smokers,% 9.6 10.0 8.6
Former smokers,% 30.3 24.1 45.9
Alcohol consumption
Non drinker,% 35.5 39.5 32.2
Mean intake among drinkers, g/day 16.3 13.0 22.3
Body mass index $30 kg/ma,%1 18.8 19.9 16.3
Comorbidities
History of hypertensionb,% 46.8 46.4 47.7
History of depressionb,% 29.6 31.8 24.0
History of cancerb,% 12.5 12.1 13.5
History of diabetesb,% 11.0 10.1 13.0
History of myocardial infarctionb,% 5.1 3.3 9.4
History of strokeb,% 3.4 3.2 3.0
Additional of comorbidities to RLSb 2.6 2.6 2.4
1 additional comorbidityb,% 18.3 17.6 19.8
2 additional comorbiditiesb,% 24.3 24.9 22.7
$5 additional comorbiditiesb,% 14.2 14.8 12.8
abased on self-reported weight and height.
bself-reported physician diagnosis.
doi:10.1371/journal.pone.0094821.t001
RLS and Health Status
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statistically significant. All analyses were done with STATA 9.0
(StatCorp LP, College Station, TX, USA).
Results
In total 2751 patients were recruited into the COR-Study.
Table 1 summarizes characteristics of the study population at
baseline and life time prevalences of self reported physician-
diagnosed comorbidities.
From a list of 17 comorbidities, partly important as being
related to RLS, 11.2% of the participants reported no additional
comorbidity at baseline. Complete information for the IRLS in all
five questionnaires was provided by 84.2% of the participants.
Mean IRLS scores differed only slightly between the five
assessments (Table 2), with men consistently reporting higher
scores.
Across all five assessments RLS severity increased with age up to
the age group of 45–54 years (figure 1) but not further.
Figures 2a and b show self-reported daily variations in the
severity of the two key symptoms of RLS, ‘‘urge to move’’ and
‘‘dysaesthesia’’, implemented in the 7-day diary of Q2 (6-months
follow-up). The figures summarize participant perceptions of these
two symptoms as being ‘‘severe’’ during four time periods every
day. The four lines in each figure represent participants in the
RLS categories of mild, moderate, severe and very severe, derived
from the IRLS summary score. Subjects with severe and very
severe RLS particularly reported a distinct circadian pattern for
both symptoms with expected peaks in the time periods 6.00
p.m.to midnight and midnight to 8.00 a.m.
Table 2 shows changes in mean scores of RLS severity-, self-
perceived health status- (SF-36), depressive symptom scores (CES-
D) and sleep related problems (PSQI) in the four assessments. The
mean IRLS score decreased by 2.2 points over the 3 years course.
The SF-36 subscore changes were small, resulting in small
decreases in both the physical- and the mental component
summary score.
At baseline 53.2% of the participants of the COR-Study had a
score of $16 on the CES-D indicating a high likelihood for an
ongoing episode of clinical depression. The mean CES-D score
over time remained unchanged and was constantly higher in
women than in men. 30.9% of the study participants had
persistent high CES-D scores indicating a high likelihood of a
clinical diagnosis of major depression. Depressive symptoms were
Table 2.Mean values in RLS severity (IRLS), quality of life (SF-36), depression (CES-D) and sleep (PSQI) scales at baseline 12-months,
24-months and 36-months follow-up.
Scale Baseline (Q1)
12-months F-up
(Q3)
24-months F-up
(Q4)
36-months F-up
(Q5) p-valuea
RLS severity scale (IRLS), mean 25.2 25.2 23.2 23.0 ,0.01
Short-Form 36 Health Survey (SF-36), means
Physical Functioning (PF) 64.1 65.0 62.9 60,3 ,0.01
Role Physical (RP) 50.1 50.5 47.4 46.9 ,0.01
Role Emotional (RE) 67.7 68.4 67.1 66.2 ,0.01
Social Functioning (SF) 68.6 69.0 68.6 67.3 ,0.01
Mental Health (MH) 63.2 63.2 62.4 62.2 ,0.01
Bodily Pain (BP) 50.4 50.5 50.3 50.6 0.22
Vitality (VT) 46.6 47.1 47.2 45.8 ,0.01
General Health (GH) 49.9 49.7 50.9 50.1 0.05
Physical Component Summary 39.2 39.3 38.9 38.4 ,0.01
Mental Component Summary 46.1 46.2 46.2 45.8 0.24
Center for Epidemiologic Studies Depression Scale
(CES-D)
17.9 17.7 17.8 18.1 0.07
Depressive affect 4.1 4.2 4.1 4.3 0.04
Somatic symptoms 6.5 6.5 6.6 6.7 ,0.01
Positive affect 6.6 6.5 6.5 6.6 0.23
Interpersonal relations 0.4 0.4 0.4 0.4 0.03
Pittsburgh Sleep Quality Index (PSQI) 10.3 10.4 10.6 10.7 ,0.01
ap-value for difference between assessments according to one-way repeated measures ANOVA.
doi:10.1371/journal.pone.0094821.t002
Figure 1. Mean IRLSa score according to six age groups at
baseline, 6-, 12- 24- and 36-months follow-up.
doi:10.1371/journal.pone.0094821.g001
RLS and Health Status
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strongly related to RLS severity, increasing from a CES-D score of
11.3 among those with mild symptoms (#10 points IRLS) to 24.5
in those with high severity (.30 points IRLS), after controlling for
age and gender (not shown). Average PSQI-scores increased
slightly over the course of 3 years, indicating a small worsening in
sleep quality.
Applying our definition of ‘clinically relevant change’ (IRLS65
points), 27.3% of the participants of the COR-Study ‘‘improved’’,
12.5% ‘‘worsened’’ and 60.2% of the subjects showed ‘‘no
change’’ over the course of three years. Table 3 describes
characteristics in health status scores in these three groups
according to the time of assessment.
Small variations indicate a slight worsening of the CES-D- and
PSQI scores as well as the physical and mental component
summary scores of the SF-36 among those with ‘‘unchanged’’ RLS
severity. In contrast, the ‘‘worsened’’ group reported considerable
worse scores in all categories. The change of mean RLS severity
over time followed a rather consistent trend across the five points
of assessment. Those with a worsening of symptoms had a rather
low RLS severity level at baseline while the group with improved
symptom severity started at a relatively high level (28.4 IRLS
points). Compared to the changes in the IRLS, the changes in the
depression, quality of life and sleep scales were rather small.
Figure 2. A) Short term variation of the RLS minimal criterion ‘‘urge to move’’ in the 7-day diary, according to IRLSa score and time of the day. B)
Short term variation of the RLS minimal criterion ‘‘dysaesthesia’’ in the 7-day diary according IRLSa score and time of the day.
doi:10.1371/journal.pone.0094821.g002
RLS and Health Status
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In multivariable linear regression analyses we analysed the effect
of a change in IRLS between baseline and 36-months follow-up on
the changes in CES-D-, PSQI and the SF-36 summary scores in
separate models, adjusted for gender, age, number of comorbid-
ities, RLS duration and the specific scale’s baseline score. An
increase of the IRLS score by one point yielded a significant
increase of the CES-D score by 0.21 points (95% CI, 0.17–0.25).
The first also yielded a significant increase of the PSQI by 0.13
points (95% CI, 0.11–0.15) and significant decreases in the
physical (20.12; 95% CI, 20.17–20.09) and mental component
summary scores (20.16; 95% CI, 20.20–20.11) of the SF-36 (not
shown).
Discussion
The Course of RLS (COR-S) Study analysed short (7-day) and
long-term (36-months) variations in RLS severity over time and
their influence on quality of life, depression and sleep quality.
Among participants an average improvement of less than 1 point
in RLS severity per 12 months was observed during 3 years of
follow-up. We consider this annual change as clinically not
relevant. RLS severity increased with age reaching a plateau in the
age group 45–54 years in all assessments. This finding indicates a
stable average severity level at least under medical treatment from
midlife on. Thus, our results do not support the hypothesis that
‘‘RLS worsens with age in the elderly’’. A worsening in RLS
severity over three years was significantly associated with more
depressive symptoms, worse sleep quality and lower quality of life.
The short-term variation of the two key symptoms of RLS ‘‘urge to
move’’ and ‘‘dysaesthesia’’ showed distinctive circadian patterns
with rhythms that were strongly related to RLS severity.
An increase in RLS prevalence with age has been found in
many cross sectional studies of the general population [1,2]. No
data have been published evaluating the long-term course of RLS
symptoms beyond the duration of clinical trials. Satija and Ondo
[14] described a progressive symptomatology with increasing age
during the first seven to eight decades, with an improvement of
RLS symptoms in the ninth decade. In contrast we found an
association of severity with age only up to the age group 45–54
years. Beyond that group average symptom severity did not
increase with higher ages in treated RLS participants.
60% percent of the study population did not experience a
relevant symptom change over the course of three years. Almost
every participant was on RLS medication at baseline and during
follow-up including a single medication or combinations of up to
five different drugs. However, 45.9% of the study participants
reported a change of at least one RLS specific drug, i.e. either a
stop or a new intake of a dopaminergic drug, dopamine receptor
agonist, an opioid, an antiepileptic drug or a benzodiazepine.
Many studies have described an influence of RLS on quality of
life [15]. Direct (dyseasthesia, urge to move) and indirect (sleep
deprivation and disruption of sleep) effects of RLS negatively
influence the self perceived health status. Our findings contrast
results from clinical trials that indicate an improvement of quality
of life scores with decreasing RLS severity [16]. This difference
Table 3. Clinical characteristics and differences in health status according to changes in RLS severity (IRLSc) over 36 months.
36 months changeb in RLS severity
Worsening 12.5% Unchanged 60.2% Improvement 27.3% p-value
Age at baseline, years 65.8 65.5 64.6 0.03*
Women, % 78.3 71.9 71.2 0.06a
Men; % 21.7 28.1 28.8
Mean IRLS3 score at baseline 16.0 25.3 28.4 ,0.01*
Mean IRLS3 score at 6-months follow-up 19.7 23.5 21.9 ,0.01*
Mean IRLS3 score at 12-months follow-up 23.5 25.7 24.4 ,0.01*
Mean IRLS3 score at 24-months follow-up 22.2 24.5 20.8 ,0.01*
Mean IRLS3 score at 36-months follow-up 26.5 25.1 16.6 ,0.01*
Center for Epidemiologic Studies Depression Scale (CES-D)
Mean score baseline 14.6 17.9 18.4 ,0.01*
Mean score 36-months follow- up 18.8 18.7 16.3 ,0.01*
Pittsburgh Sleep Quality Index (PSQI)
Mean score baseline 8.7 10.6 10.5 ,0.01*
Mean score 36-months follow-up 10.3 11.1 9.8 ,0.01*
Physical Component Summary (PCS of SF-36)
Mean score baseline 41.3 39.5 39.8 0.07*
Mean score 36-months follow-up 38.4 37.7 40.0 ,0.01*
Mental Component Summary (MCS of SF-36)
Mean score baseline 49.1 45.9 45.8 0.01*
Mean score 36-months follow-up 45.8 45.2 47.1 0.01*
*p for differences between the 3 groups derived from one-way analysis of variance (ANOVA) unless otherwise noted.
aChi-square test for the difference between gender.
bChange in the International Restless Legs Study Group (IRLSSG) Rating Scale for severity of RLS between baseline and 36 months follow-up: worsening = increase in
score by .5 points, unchanged= change in score not more than 65 points, improving = decrease in score .5 points.
cInternational Restless Legs Study Group Rating Scale for severity of RLS (IRLS).
doi:10.1371/journal.pone.0094821.t003
RLS and Health Status
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might be contributed to an effect of ageing in this cohort due to the
already high mean age of 65.9 years in the cohort at baseline.
Depressed mood, social isolation as well as a decrease in self-
reported mental health [1,17] have been found in RLS cases.
Cross-sectional studies have revealed an association of RLS
severity with subjective sleep quality, but not with self-rated
depressive symptoms [18]. In two studies, also applying the CES-
D as a self-administered rating scale [3,19] higher CES-D scores in
RLS cases compared to non-affected individuals and higher CES-
D scores in cases with more severe RLS were found. In the COR-
Study high mean CES-D scores with no change over time indicate
that the majority of study participants had constant clinically
relevant depressive symptoms. Improvement or worsening of RLS
severity went along with rather modest changes in depression
scores of 2 to 4 points during 3 years of follow-up. Interestingly a
worsening in RLS severity was associated with a change in the
depression score that was twice as high as the one that was
associated with an improvement of RLS severity.
The COR-Study participants estimated their sleep quality as
moderately impaired. It is known that insomnia is a risk factor for
depressive episodes and increases the likelihood of recurrence of
depression [20], but depression may also cause insomnia. Sleep-
related symptoms are relevant contributors to the diagnosis of
depressive disorders and might thus be a connecting link, even the
most important contributing factor between RLS and depression.
The COR-Study has several strengths and limitations. It
includes a large number of study participants from two different
countries. It prospectively assesses important disease characteristics
and potential consequences in regular intervals over a long time
establishing a true time sequence between severity and subsequent
outcomes. Implementing a 7-day diary into one of the question-
naires enabled the documentation of short-term variation in
symptom characteristics.
A limitation of this study is that all diagnoses, comorbidities and
medications are self-reported since the study is conducted by
mailed questionnaire. This might cause a misclassification of
comorbidities in some cases due to insufficient knowledge about
diagnoses among the participants. The COR-study is conducted
among participants of RLS patient organizations, who most likely
represent a selection towards RLS patients with a special health
awareness compared to all RLS affected individuals. However, it
cannot be ruled out that patients suffering from a higher degree of
severity of RLS were less likely to participate in the study. In
addition a misclassification of RLS status cannot be excluded. We
addressed this problem by including a so-called ‘‘gold standard’’
group with RLS, comprising about 6% of the study population.
The reported results for this ‘‘gold standard’’ group were not
different from the other study participants, supporting the
robustness of our findings.
In summary in large cohort of RLS patient organization
members mean RLS severity was rather stable over the course of
three years, indicating ‘‘little change’’, despite considerable
changes in individual RLS medications. A worsening in RLS
severity caused small to moderate negative effects on quality of life,
depressive symptoms and sleep quality. No evidence was found to
support the hypothesis that age is a determinant of progression of
RLS beyond age 55 years. More research into treatment wish and
medication adherence among RLS patients is needed, to enable
informed choices for affected individuals before starting long-term
treatments.
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